{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:41:31Z","timestamp":1778114491979,"version":"3.51.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Anesth\/J Can Anesth"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/bf03022528","type":"journal-article","created":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T20:25:18Z","timestamp":1241382318000},"page":"994-1003","source":"Crossref","is-referenced-by-count":41,"title":["Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications","Revue sommaire sur les implications anesth\u00e9siques de l\u2019\u0153d\u00e8me de Quincke et des inhibiteurs de l\u2019enzyme de conversion de l\u2019ngiotensine"],"prefix":"10.1007","volume":"53","author":[{"given":"Putul","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grainne","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03022528_CR1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","volume":"260","author":"EE Slater","year":"1988","unstructured":"Slater EE, Merril DD, Guess HA, et al. Clinical profile of angioedema with angiotensin-converting enzyme inhibition. JAMA 1988, 260:967\u201370.","journal-title":"JAMA"},{"key":"BF03022528_CR2","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1161\/01.CIR.0000075957.16003.07","volume":"108","author":"NK Sweitzer","year":"2003","unstructured":"Sweitzer NK. What is an angiotensin converting enzyme inhibitor? Circulation 2003; 108:e16\u20138.","journal-title":"Circulation"},{"key":"BF03022528_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","volume":"60","author":"NJ Brown","year":"1996","unstructured":"Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60:8\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"BF03022528_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199818030-00003","volume":"18","author":"W Vleeming","year":"1998","unstructured":"Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998; 18:171\u201388.","journal-title":"Drug Saf"},{"key":"BF03022528_CR5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1445-5994.1996.tb00624.x","volume":"26","author":"GM Gabb","year":"1996","unstructured":"Gabb GM, Ryan P, Wing LM, Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996; 26:777\u201382.","journal-title":"Aust N Z J Med"},{"key":"BF03022528_CR6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1378\/chest.126.2.400","volume":"126","author":"D Sondhi","year":"2004","unstructured":"Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest 2004; 126:400\u20134.","journal-title":"Chest"},{"key":"BF03022528_CR7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2044.2004.03614.x","volume":"59","author":"Rai","year":"2004","unstructured":"Rai, MR, Amen F, Idrees F. Angiotensin-converting enzyme inhibitor related angioedema and the anaesthetist. Anaesthesia 2004; 59:283\u20139.","journal-title":"Anaesthesia"},{"key":"BF03022528_CR8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1288\/00005537-199203000-00005","volume":"102","author":"CA Megerian","year":"1992","unstructured":"Megerian CA, Arnold JE, Berger M. Angioedema: 5 years\u2019 experience, with a review of the disorder\u2019s presentation and treatment. Laryngoscope 1992; 102:256\u201360.","journal-title":"Laryngoscope"},{"key":"BF03022528_CR9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/bmj.304.6832.941","volume":"304","author":"T Hedner","year":"1992","unstructured":"Hedner T, Samuelsson O, Lunde H, Lindholm L, Andren L, Wiholm BE. Angio-oedema in relation to the treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304:941\u20136.","journal-title":"BMJ"},{"key":"BF03022528_CR10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0735-6757(93)90166-9","volume":"11","author":"EC Pigman","year":"1993","unstructured":"Pigman EC, Scott JL. Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med 1993; 11:350- 4.","journal-title":"Am J Emerg Med"},{"key":"BF03022528_CR11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s001010050225","volume":"44","author":"C Maier","year":"1995","unstructured":"Maier C. Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor (German). Anaesthetist 1995; 44:875\u20139.","journal-title":"Anaesthetist"},{"key":"BF03022528_CR12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.joms.2004.12.010","volume":"63","author":"F O\u2019Ryan","year":"2005","unstructured":"O\u2019Ryan F, Poor DB, Hattori M. Intraoperative angioedema induced by angiotensin-converting enzyme inhibitors: overview and case report. J Oral Maxillofac Surg 2005; 63:551\u20136.","journal-title":"J Oral Maxillofac Surg"},{"key":"BF03022528_CR13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0278-2391(96)90550-9","volume":"54","author":"KU Ogbureke","year":"1996","unstructured":"Ogbureke KU, Cruz C, Johnson JV, Helfrick JF. Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. J Oral Maxillofac Surg 1996; 54:917\u201320.","journal-title":"J Oral Maxillofac Surg"},{"key":"BF03022528_CR14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1378\/chest.102.3.871","volume":"102","author":"M Jain","year":"1992","unstructured":"Jain M, Armstrong L, Hall J. Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy. Chest 1992; 102:871\u20134.","journal-title":"Chest"},{"key":"BF03022528_CR15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1398-9995.1997.tb01024.x","volume":"52","author":"PI Schiller","year":"1997","unstructured":"Schiller PI, Messmer SL, Haefeli WE, Schlienger RG, Bircher AJ. Angiotensin-converting enzyme induced angioedema: late onset, irregular course, and potential role of triggers. Allergy 1997; 52:432\u20135.","journal-title":"Allergy"},{"key":"BF03022528_CR16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1177\/106002809202601012","volume":"26","author":"JL Ulmer","year":"1992","unstructured":"Ulmer JL, Garvey MJ. Fatal angioedema associated with lisinopril. Ann Pharmacother 1992; 26:1245\u20136.","journal-title":"Ann Pharmacother"},{"key":"BF03022528_CR17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.revmed.2004.02.024","volume":"25","author":"JP Ducroix","year":"2004","unstructured":"Ducroix JP, Outurquin S, Benabes-Jezraoui B, et al. Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases (French). Rev Med Interne 2004; 25:501\u20136.","journal-title":"Rev Med Interne"},{"key":"BF03022528_CR18","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1520\/JFS13333J","volume":"37","author":"DR Jason","year":"1992","unstructured":"Jason DR. Fatal angioedema associated with captopril. J Forensic Sci 1992; 37:1418\u201321.","journal-title":"J Forensic Sci"},{"key":"BF03022528_CR19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2169\/internalmedicine.32.308","volume":"32","author":"Y Oike","year":"1993","unstructured":"Oike Y, Ogata Y, Higashi D, Matsumura T, Numata Y. Fatal angioedema associated with enalapril. Intern Med 1993; 32:308\u201310.","journal-title":"Intern Med"},{"key":"BF03022528_CR20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1520\/JFS15129J","volume":"46","author":"DE Dean","year":"2001","unstructured":"Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001; 46:1239\u201343.","journal-title":"J Forensic Sci"},{"key":"BF03022528_CR21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","volume":"356","author":"FH Messerli","year":"2000","unstructured":"Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356:608\u20139.","journal-title":"Lancet"},{"key":"BF03022528_CR22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.jhh.1001714","volume":"18","author":"JM Neutel","year":"2004","unstructured":"Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18:599\u2013606.","journal-title":"J Hum Hypertens"},{"key":"BF03022528_CR23","doi-asserted-by":"crossref","unstructured":"Anonymous. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429\u201335.","DOI":"10.1056\/NEJM198706043162301"},{"key":"BF03022528_CR24","doi-asserted-by":"crossref","unstructured":"Anonymous. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"BF03022528_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325, 303\u201310.","journal-title":"N Engl J Med"},{"key":"BF03022528_CR26","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg, R, Yusuf, S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450\u20136.","journal-title":"JAMA"},{"key":"BF03022528_CR27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJM199501123320210","volume":"332","author":"MA Pfeffer","year":"1995","unstructured":"Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med 1995; 332:118\u201320.","journal-title":"N Engl J Med"},{"key":"BF03022528_CR28","first-page":"31","volume":"2","author":"HL Elliott","year":"1994","unstructured":"Elliott HL. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment. Blood Press Suppl 1994; 2:31\u20134.","journal-title":"Blood Press Suppl"},{"key":"BF03022528_CR29","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1185\/030079904X4185","volume":"20","author":"ME Bertrand","year":"2004","unstructured":"Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004; 20:1559\u201369.","journal-title":"Curr Med Res Opin"},{"key":"BF03022528_CR30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yosuf","year":"2000","unstructured":"Yosuf S, Sleight P, Pogue J, Borsch J, Davies R, Dagenais G. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145\u201353.","journal-title":"N Engl J Med"},{"key":"BF03022528_CR31","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0735-1097(01)01683-7","volume":"38","author":"S Hunt","year":"2001","unstructured":"Hunt S, Baker DW, Chin MH, et al. ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology\/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001; 38:2101\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"BF03022528_CR32","doi-asserted-by":"crossref","unstructured":"Anonymous. Failure to treat heart failure (Editorial). Lancet 1992; 339: 278\u20139.","DOI":"10.1016\/0140-6736(92)91339-A"},{"key":"BF03022528_CR33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/euhj.2000.2493","volume":"22","author":"JG Cleland","year":"2001","unstructured":"Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001; 22:623\u20136.","journal-title":"Eur Heart J"},{"key":"BF03022528_CR34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.transproceed.2005.01.043","volume":"37","author":"D Montanaro","year":"2005","unstructured":"Montanaro D, Gropuzzo M, Tulissi P, et al. Renoprotective effect of early inhibition of the renin- angiotensin system in renal transplant recipients. Transplant Proc 2005; 37:991\u20133.","journal-title":"Transplant Proc"},{"key":"BF03022528_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685\u201393.","journal-title":"Arch Intern Med"},{"key":"BF03022528_CR36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00002018-200326130-00006","volume":"26","author":"ML Bouvy","year":"2003","unstructured":"Bouvy ML, Heer dink ER, Hoes AW, Leufkens HG. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26:983\u20139.","journal-title":"Drug Saf"},{"key":"BF03022528_CR37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/106002809603000718","volume":"30","author":"MJ Cziraky","year":"1996","unstructured":"Cziraky MJ, Mehr a IV, Wilson M, Bakris GL. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother 1996; 30:791\u2013801.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"BF03022528_CR38","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1136\/hrt.72.3_Suppl.S38","volume":"72","author":"CE Mogensen","year":"1994","unstructured":"Mogensen CE. Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 1994; 72(3 Suppl):S38\u201345.","journal-title":"Br Heart J"},{"key":"BF03022528_CR39","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","volume":"26","author":"K Rossing","year":"2003","unstructured":"Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26:2268\u201374.","journal-title":"Diabetes Care"},{"key":"BF03022528_CR40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/diacare.26.1.150","volume":"26","author":"K Rossing","year":"2003","unstructured":"Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 2003; 26:150\u20135.","journal-title":"Diabetes Care"},{"key":"BF03022528_CR41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","volume":"57","author":"S Andersen","year":"2000","unstructured":"Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57:601\u20136.","journal-title":"Kidney Int"},{"key":"BF03022528_CR42","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","volume":"329","author":"GF Strippoli","year":"2004","unstructured":"Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review. BMJ 2004; 329:828\u201338.","journal-title":"BMJ"},{"key":"BF03022528_CR43","doi-asserted-by":"crossref","unstructured":"Anonymous. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253\u20139.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"BF03022528_CR44","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","volume":"134","author":"ACE Inhibitors in Diabetic Nephropathy Trialist Group","year":"2001","unstructured":"ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134:370\u20139.","journal-title":"Ann Intern Med"},{"key":"BF03022528_CR45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","volume":"116","author":"UC Brewster","year":"2004","unstructured":"Brewster UC, Perazella MA. The renin-angiotensin- aldosterone system and the kidney: effects on kidneydisease. Am J Med 2004; 116:263\u201372.","journal-title":"Am J Med"},{"key":"BF03022528_CR46","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939\u201345.","journal-title":"N Engl J Med"},{"key":"BF03022528_CR47","doi-asserted-by":"crossref","unstructured":"Anonymous. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group. Lancet 1997; 349: 1857\u201363.","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"BF03022528_CR48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1262-3636(07)70146-5","volume":"30","author":"AJ Scheen","year":"2004","unstructured":"Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30:487\u201396.","journal-title":"Diabetes Metab"},{"issue":"9","key":"BF03022528_CR49","doi-asserted-by":"crossref","first-page":"84S","DOI":"10.1093\/ajh\/7.9.84S","volume":"7","author":"L Bohlen","year":"1994","unstructured":"Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7(9 Pt 2):84S-92S.","journal-title":"Am J Hypertens"},{"key":"BF03022528_CR50","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"BF03022528_CR51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","volume":"32","author":"NJ Brown","year":"1998","unstructured":"Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32:965\u201371.","journal-title":"Hypertension"},{"key":"BF03022528_CR52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","volume":"42","author":"M Furuhashi","year":"2003","unstructured":"Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42:76\u201381.","journal-title":"Hypertension"},{"key":"BF03022528_CR53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.0000132568.71409.a2","volume":"44","author":"AM Sharma","year":"2004","unstructured":"Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44:12\u20139.","journal-title":"Hypertension"},{"key":"BF03022528_CR54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","volume":"257","author":"Y Arita","year":"1999","unstructured":"Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF03022528_CR55","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941\u20136.","journal-title":"Nat Med"},{"key":"BF03022528_CR56","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/01.CIR.0000042707.50032.19","volume":"106","author":"Y Okamoto","year":"2002","unstructured":"Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106:2767\u201370.","journal-title":"Circulation"},{"key":"BF03022528_CR57","unstructured":"Reid IA. Vasoactive peptides.In: Katzung BG (Ed.). Basic and Clinical Pharmaclogy, 9th ed. McGraw Hill; 2003."},{"key":"BF03022528_CR58","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1213\/00000539-199808000-00047","volume":"87","author":"NF Jensen","year":"1998","unstructured":"Jensen NF, Weiler JM. C1 esterase inhibitor deficiency, airway compromise, and anesthesia. Anesth Analg 1998; 87:480\u20138.","journal-title":"Anesth Analg"},{"key":"BF03022528_CR59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bpg.2004.11.011","volume":"19","author":"FS Rosen","year":"2005","unstructured":"Rosen FS, Davis AE III. Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol 2005; 19:251\u201361.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"BF03022528_CR60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0194-5998(99)70182-8","volume":"121","author":"E Ishoo","year":"1999","unstructured":"Ishoo E, Shah UK, Grillone G A, StramJR, Fuleihan NS. Predicting airway risk in angioedema: staging system based on presentation. Otolaryngol Head Neck Surg 1999; 121:263\u20138.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"BF03022528_CR61","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1212\/01.WNL.0000058840.66596.1A","volume":"13","author":"MD Hill","year":"2003","unstructured":"Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 13:1525\u20137.","journal-title":"Neurology"},{"key":"BF03022528_CR62","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/01.STR.0000017284.77838.87","volume":"33","author":"G Molinaro","year":"2002","unstructured":"Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 2002; 33:1712\u20136.","journal-title":"Stroke"},{"key":"BF03022528_CR63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/00002018-200124080-00004","volume":"24","author":"A Agostoni","year":"2001","unstructured":"Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24:599\u2013606.","journal-title":"Drug Saf"},{"key":"BF03022528_CR64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZH Israili","year":"1992","unstructured":"Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234\u201342.","journal-title":"Ann Intern Med"},{"key":"BF03022528_CR65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103\u201311.","journal-title":"Am J Hypertens"},{"key":"BF03022528_CR66","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s001340050413","volume":"23","author":"R Agah","year":"1997","unstructured":"Agah R, Bandi V, Guntupalli KK. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 1997; 23:793\u20136.","journal-title":"Intensive Care Med"},{"key":"BF03022528_CR67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2500\/108854192778878845","volume":"13","author":"L Bielory","year":"1992","unstructured":"Bielory L, Lee SS, Holland CL, Jaker M. Long-acting ACE inhibitor-induced angioedema. Allergy Proc 1992; 13:85\u20137.","journal-title":"Allergy Proc"},{"key":"BF03022528_CR68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0735-6757(92)90010-U","volume":"10","author":"RS Rees","year":"1992","unstructured":"Rees RS, Bergman J, Ramirez-Alexander R. Angioedema associated with lisinopril. Am J Emerg Med 1992; 10:321\u20132.","journal-title":"Am J Emerg Med"},{"key":"BF03022528_CR69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00045391-200405000-00008","volume":"11","author":"W Guo","year":"2004","unstructured":"Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients non responsive to previous antihypertensive therapy: a large US community trial. Am J Ther 2004; 11:199\u2013205.","journal-title":"Am J Ther"},{"key":"BF03022528_CR70","first-page":"362","volume":"129","author":"C Schuster","year":"1999","unstructured":"Schuster C, Reinhart WH, Hartmann K, Kuhn M. Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases (German). Schweiz Med Wochenschr 1999; 129:362\u20139.","journal-title":"Schweiz Med Wochenschr"},{"key":"BF03022528_CR71","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1055\/s-2007-994824","volume":"33","author":"H Wernze","year":"1998","unstructured":"Wernze H. ACE inhibitor-induced angioedema: remarkable new perspectives for intensive care\/emergency medicine (German). Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33:637\u201341.","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"BF03022528_CR72","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1524-6175.2001.00830.x","volume":"3","author":"LM Prisant","year":"2001","unstructured":"Prisant LM. Angioneurotic edema. J Clin Hypertens (Greenwich) 2001; 3:262\u20133.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BF03022528_CR73","first-page":"205","volume":"1","author":"WE Golden","year":"1993","unstructured":"Golden WE, Cleves MA, Heard JK, Brasher R, McKinney P, Johnston JC. Frequency and recognition of angiotensin-converting enzyme inhibitor-associated angioneurotic edema. Clin Perform Qual Health Care 1993; 1:205\u20137.","journal-title":"Clin Perform Qual Health Care"},{"key":"BF03022528_CR74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0162-3109(99)00107-1","volume":"44","author":"A Agostoni","year":"1999","unstructured":"Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin- converting enzyme inhibitors. Immunopharmacology 1999; 44:21\u20135.","journal-title":"Immunopharmacology"},{"issue":"Suppl2","key":"BF03022528_CR75","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/61.suppl_2.S4","volume":"61","author":"KF Adams","year":"2004","unstructured":"Adams KF Jr. Pathophysiologic role of the renin- angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health-Syst Pharm 2004; 61(Suppl2):S4\u201313.","journal-title":"Am J Health-Syst Pharm"},{"key":"BF03022528_CR76","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2044.1986.tb13127.x","volume":"41","author":"PA Razis","year":"1986","unstructured":"Razis PA, Coulson IH, Gould TR, Findley IL. Acquired C1 esterase inhibitor deficiency. Anaesthesia 1986; 41:838\u201340.","journal-title":"Anaesthesia"},{"key":"BF03022528_CR77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2133.1997.tb14887.x","volume":"136","author":"RA Sabroe","year":"1997","unstructured":"Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997, 136:153\u20138.","journal-title":"Br J Dermatol"},{"key":"BF03022528_CR78","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0162-3109(99)00133-2","volume":"43","author":"C Blais","year":"1999","unstructured":"Blais C Jr,Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999; 43:293\u2013302.","journal-title":"Immunopharmacology"},{"key":"BF03022528_CR79","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.102.038067","volume":"303","author":"G Molinaro","year":"2002","unstructured":"Molinaro G, Cugno M, Perez M, et al. Angiotensin- converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des- arginine(9)-bradykinin. J Pharmacol Exp Ther 2002; 303:232\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF03022528_CR80","first-page":"133","volume":"26","author":"O Steinbach","year":"2001","unstructured":"Steinbach O, Schweder R, Freitag B. C1-esterase inhibitor in ACE inhibitor-induced severe angioedema of the tongue (German). Anaesthesiol Reanim 2001; 26:133\u20137.","journal-title":"Anaesthesiol Reanim"},{"key":"BF03022528_CR81","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1081-1206(10)62496-9","volume":"86","author":"GI Kleiner","year":"2001","unstructured":"Kleiner GI, Giclas P, Stadtmauer G, Cunningham-Rundles C. Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma Immunol 2001; 86:461\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"BF03022528_CR82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2125.2004.02268.x","volume":"59","author":"M Bas","year":"2005","unstructured":"Bas M, Hoffmann TK, Bier H, Kojda G. Increased C- reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005; 59:233\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"BF03022528_CR83","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2125.1999.00093.x","volume":"48","author":"CR Gibbs","year":"1999","unstructured":"Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48:861\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"BF03022528_CR84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1081-1206(10)62723-8","volume":"82","author":"J Abbosh","year":"1999","unstructured":"Abbosh J, Anderson JA, Levine AB, Kupin WL. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol 1999; 82:473\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"BF03022528_CR85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","volume":"10","author":"T Morimoto","year":"2004","unstructured":"Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10:499\u2013509.","journal-title":"J Eval Clin Pract"},{"key":"BF03022528_CR86","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/000348940111000906","volume":"110","author":"AG Chiu","year":"2001","unstructured":"Chiu AG, New kirk KA, Davidson BJ, Burningham AR, Krowiak EJ, Deeb ZE. Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann Otol Rhinol Laryngol 2001; 110:834\u201340.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"BF03022528_CR87","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jama.1997.03550030072037","volume":"278","author":"NJ Brown","year":"1997","unstructured":"Brown NJ, Snow den M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 1997; 278:232\u20133.","journal-title":"JAMA"},{"key":"BF03022528_CR88","first-page":"187","volume":"13","author":"F Marceau","year":"1997","unstructured":"Marceau F. Is there a role for bradykinin in the therapeutic and side effects of angiotensin-converting enzyme inhibitors? Can J Cardiol 1997, 13:187\u201394.","journal-title":"Can J Cardiol"},{"key":"BF03022528_CR89","first-page":"10","volume":"1)","author":"T Thompson","year":"P","unstructured":"Thompson T, Frable MA. Drug-induced, life threatening angioedema revisited. Laryngoscope 1993; 103(1 Pt 1):10\u20132.","journal-title":"Laryngoscope 1993; 103(1"},{"key":"BF03022528_CR90","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1097\/00005537-200012000-00007","volume":"110","author":"BL Bentsianov","year":"2000","unstructured":"Bentsianov BL, Parhiscar A, Azer M, Har-El G. The role of fiberoptic nasopharyngoscopy in the management of the acute airway in angioneurotic edema. Laryngoscope 2000; 110:2016\u20139.","journal-title":"Laryngoscope"},{"key":"BF03022528_CR91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00000441-200208000-00011","volume":"324","author":"TD Schmidt","year":"2002","unstructured":"Schmidt TD, McGrath KM. Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am J Med Sci 2002; 324:106\u20138.","journal-title":"Am J Med Sci"},{"key":"BF03022528_CR92","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5694\/j.1326-5377.1996.tb124991.x","volume":"165","author":"RJ Mullins","year":"1996","unstructured":"Mullins RJ, Shanahan TM, Dobson RT. Visceral angioedema related to treatment with an ACE inhibitor. Med J Aust 1996; 165:319\u201321.","journal-title":"Med J Aust"},{"key":"BF03022528_CR93","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/000348940111000801","volume":"110","author":"EG Cohen","year":"2001","unstructured":"Cohen EG, Soliman AM. Changing trends in angioedema. Ann Otol Rhinol Laryngol 2001; 110:701\u20136.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"BF03022528_CR94","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archinte.164.8.910","volume":"164","author":"M Cicardi","year":"2004","unstructured":"Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004; 164:910\u20133.","journal-title":"Arch Intern Med"},{"key":"BF03022528_CR95","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1081-1206(10)61766-8","volume":"92","author":"MR Warrier","year":"2004","unstructured":"Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensin converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 2004; 92:573\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"BF03022528_CR96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1067\/mai.2002.121313","volume":"109","author":"MY Karim","year":"2002","unstructured":"Karim MY, Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol 2002; 109:370\u20131.","journal-title":"J Allergy Clin Immunol"},{"key":"BF03022528_CR97","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1345\/aph.17388","volume":"32","author":"GB Pylypchuk","year":"1998","unstructured":"Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32:1060\u20136.","journal-title":"Ann Pharmacother"},{"key":"BF03022528_CR98","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/archinte.158.18.2063","volume":"158","author":"EW Rijnsoever Van","year":"1998","unstructured":"Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158:2063\u20135.","journal-title":"Arch Intern Med"},{"key":"BF03022528_CR99","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/00005537-200110000-00011","volume":"111","author":"AG Chiu","year":"2001","unstructured":"Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001; 111:1729\u201331.","journal-title":"Laryngoscope"},{"key":"BF03022528_CR100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00002018-200225020-00001","volume":"25","author":"LG Howes","year":"2002","unstructured":"Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002; 25:73\u20136.","journal-title":"Drug Saf"}],"container-title":["Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03022528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03022528\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03022528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T03:08:26Z","timestamp":1710299306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03022528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["BF03022528"],"URL":"https:\/\/doi.org\/10.1007\/bf03022528","relation":{},"ISSN":["0832-610X","1496-8975"],"issn-type":[{"value":"0832-610X","type":"print"},{"value":"1496-8975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}